• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

去氢表雄酮抗肥胖作用的另一种机制:11β-羟甾类脱氢酶 1 抑制在啮齿动物脂肪组织中的可能作用。

Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue.

机构信息

Department of Medical Biochemistry, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan.

出版信息

Steroids. 2011 Dec 20;76(14):1546-53. doi: 10.1016/j.steroids.2011.09.005. Epub 2011 Sep 14.

DOI:10.1016/j.steroids.2011.09.005
PMID:21945397
Abstract

Dehydroepiandrosterone (DHEA) has been suggested to have an anti-obesity effect; however, the mechanism underlying this effect remains unclear. The effect of DHEA on adipocytes opposes that of glucocorticoids, which potentiate adipogenesis. The key to the intracellular activation of glucocorticoids in adipocytes is 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which catalyses the production of active glucocorticoids (cortisol in humans and corticosterone in rodents) from an inactive 11-keto form (cortisone in humans and 11-dehydrocorticosterone in rodents). In humans and rodents, intracellular glucocorticoid reactivation is exaggerated in obese adipose tissue. Using differentiated 3T3-L1 adipocytes, we demonstrated that DHEA inhibited about 15.6% of 11β-HSD1 activity at a concentration of 1 μM within 10min. Inhibition was also observed in a cell-free system composed of microsomes prepared from rat adipose tissue and NADPH, a coenzyme of 11β-HSD1. A kinetic study revealed that DHEA acted as a non-competitive inhibitor of 11β-HSD1. Moreover, conversion from DHEA to estrogens was not observed by sensitive semi-micro HPLC equipped with electrochemical detector. These results indicate that the inhibition of 11β-HSD1 by DHEA depends on neither the transcriptional pathway nor the nonspecific manner. This is the first demonstration that the anti-obesity effect of DHEA is exerted by non-transcriptional inhibition of 11β-HSD1 in rodent adipocytes.

摘要

脱氢表雄酮(DHEA)被认为具有抗肥胖作用;然而,其作用机制尚不清楚。DHEA 对脂肪细胞的作用与糖皮质激素相反,后者促进脂肪生成。糖皮质激素在脂肪细胞中细胞内激活的关键是 11β-羟类固醇脱氢酶 1(11β-HSD1),它催化将无活性的 11-酮形式(人类的皮质酮和啮齿动物的 11-去氢皮质酮)转化为活性糖皮质激素(人类的皮质醇和啮齿动物的皮质酮)。在人类和啮齿动物中,肥胖脂肪组织中细胞内糖皮质激素的再激活被夸大了。使用分化的 3T3-L1 脂肪细胞,我们证明 DHEA 在 10 分钟内以 1μM 的浓度抑制了约 15.6%的 11β-HSD1 活性。在由大鼠脂肪组织制备的微粒体和 NADPH(11β-HSD1 的辅酶)组成的无细胞系统中也观察到了抑制作用。动力学研究表明 DHEA 作为 11β-HSD1 的非竞争性抑制剂起作用。此外,通过配备电化学检测器的灵敏半微 HPLC 未观察到 DHEA 转化为雌激素。这些结果表明,DHEA 对 11β-HSD1 的抑制既不依赖于转录途径,也不依赖于非特异性方式。这是首次证明 DHEA 的抗肥胖作用是通过啮齿动物脂肪细胞中 11β-HSD1 的非转录抑制来发挥的。

相似文献

1
Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue.去氢表雄酮抗肥胖作用的另一种机制:11β-羟甾类脱氢酶 1 抑制在啮齿动物脂肪组织中的可能作用。
Steroids. 2011 Dec 20;76(14):1546-53. doi: 10.1016/j.steroids.2011.09.005. Epub 2011 Sep 14.
2
17Beta-estradiol inhibits 11beta-hydroxysteroid dehydrogenase type 1 activity in rodent adipocytes.17β-雌二醇抑制啮齿动物脂肪细胞中11β-羟基类固醇脱氢酶1型的活性。
J Endocrinol. 2009 Jul;202(1):131-9. doi: 10.1677/JOE-09-0021. Epub 2009 Apr 20.
3
Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.脱氢表雄酮抑制脂肪组织中糖皮质激素作用的放大。
Am J Physiol Endocrinol Metab. 2005 May;288(5):E957-64. doi: 10.1152/ajpendo.00442.2004. Epub 2004 Dec 21.
4
Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes.白藜芦醇抑制大鼠脂肪微粒体 11β-羟甾类脱氢酶 1 型活性。
J Endocrinol. 2013 Aug 29;218(3):311-20. doi: 10.1530/JOE-13-0066. Print 2013 Sep.
5
Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).新型选择性 11β-羟甾类脱氢酶 1 型抑制剂 2-(3-苯甲酰基)-4-羟基-1,1-二氧代-2H-1,2-苯并噻嗪-2-基-1-苯乙酮(KR-66344)的抗糖尿病和抗脂肪生成作用。
Biochem Pharmacol. 2011 Apr 15;81(8):1028-35. doi: 10.1016/j.bcp.2011.01.020. Epub 2011 Feb 18.
6
Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11beta-hydroxysteroid dehydrogenase 1.己糖-6-磷酸脱氢酶调节11β-羟类固醇脱氢酶1抑制剂和替代底物的作用。
Mol Cell Endocrinol. 2009 Mar 25;301(1-2):117-22. doi: 10.1016/j.mce.2008.10.021. Epub 2008 Oct 25.
7
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.抑制11β-羟基类固醇脱氢酶1型作为一个有前景的治疗靶点。
Drug Discov Today. 2007 Jul;12(13-14):504-20. doi: 10.1016/j.drudis.2007.06.001. Epub 2007 Jun 27.
8
Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.新型选择性 11β-羟甾类脱氢酶 1 型抑制剂在饮食诱导肥胖小鼠模型中的抗糖尿病和抗脂肪生成作用。
Eur J Pharmacol. 2012 Sep 15;691(1-3):19-27. doi: 10.1016/j.ejphar.2012.06.024. Epub 2012 Jul 1.
9
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.苯扎贝特调节小鼠脂肪组织和3T3-L1脂肪细胞中11β-羟基类固醇脱氢酶1型的表达和酶活性。
Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1213-22. doi: 10.1152/ajpendo.00340.2006. Epub 2006 Dec 26.
10
Genistein inhibits glucocorticoid amplification in adipose tissue by suppression of 11β-hydroxysteroid dehydrogenase type 1.金雀异黄素通过抑制11β-羟基类固醇脱氢酶1型来抑制脂肪组织中的糖皮质激素放大作用。
Steroids. 2015 Jan;93:77-86. doi: 10.1016/j.steroids.2014.11.003. Epub 2014 Nov 28.

引用本文的文献

1
A fingerprint of 2-[F]FDG radiometabolites - How tissue-specific metabolism beyond 2-[F]FDG-6-P could affect tracer accumulation.2-[F]FDG放射性代谢物的指纹图谱——2-[F]FDG-6-P之外的组织特异性代谢如何影响示踪剂积累。
iScience. 2023 Oct 6;26(11):108137. doi: 10.1016/j.isci.2023.108137. eCollection 2023 Nov 17.
2
Recent Update on the Molecular Mechanisms of Gonadal Steroids Action in Adipose Tissue.脂肪组织中性腺类固醇作用的分子机制的最新研究进展。
Int J Mol Sci. 2021 May 14;22(10):5226. doi: 10.3390/ijms22105226.
3
Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
肾上腺皮质癌中的肿瘤微环境:免疫治疗成功的障碍?
Cancers (Basel). 2021 Apr 9;13(8):1798. doi: 10.3390/cancers13081798.
4
Glucocorticoid Resistance in Premature Adrenarche and PCOS: From Childhood to Adulthood.早产肾上腺初现和多囊卵巢综合征中的糖皮质激素抵抗:从儿童期到成年期
J Endocr Soc. 2020 Aug 4;4(9):bvaa111. doi: 10.1210/jendso/bvaa111. eCollection 2020 Sep 1.
5
Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period.绝经后时期脱氢表雄酮对代谢和心血管系统的影响。
J Mol Med (Berl). 2020 Jan;98(1):39-57. doi: 10.1007/s00109-019-01842-5. Epub 2019 Nov 12.
6
Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake.脱氢表雄酮可抑制人前体脂肪细胞增殖、分化和葡萄糖摄取的糖皮质激素作用。
Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1134-44. doi: 10.1152/ajpendo.00314.2012. Epub 2013 Sep 10.
7
Androgens for postmenopausal women's health?雄激素对绝经后女性健康有益?
Endocrine. 2012 Dec;42(3):514-20. doi: 10.1007/s12020-012-9692-1. Epub 2012 May 12.